The US Food and Drug Administration (FDA) has approved an expanded indication for Thrombate III, the Grifols-developed drug treating a rare blood-clotting disorder. Thrombate III is used to prevent hereditary antithrombin deficiency (hATd), becoming the only antithrombin concentrate (ATc) to be approved in both adult and paediatric patients. The decision by the FDA follows the extrapolation of data from two […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!